304-55-2

Applied Filters:

Keyword:'304-55-2'

Showing 1-3 of 3 results for "304-55-2" within Papers

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Richard Delarue et al.

The Lancet. Oncology, 14(6), 525-533 (2013-04-13)

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. We aimed to ascertain if a dose-dense R-CHOP regimen administered every 2 weeks (R-CHOP14) was superior

Molecular characterization of autosomal recessive chronic granulomatous disease caused by a defect of the nicotinamide adenine dinucleotide phosphate (reduced form) oxidase component p67-phox.

P J Patiño et al.

Blood, 94(7), 2505-2514 (1999-09-25)

Chronic granulomatous disease (CGD) is a rare inherited disorder of phagocytes in which defective production of microbicidal oxidants leads to severe recurrent infections. CGD is caused by mutations in any of 4 genes encoding components of nicotinamide adenine dinucleotide phosphate

Extracellular metabolites of Pseudomonas aeruginosa produce bronchoconstriction by different mechanisms.

R Forteza et al.

American journal of respiratory and critical care medicine, 149(3 Pt 1), 687-693 (1994-03-01)

Bacterial supernatants (BS) obtained from broth cultures of Pseudomonas aeruginosa cause bronchoconstriction in sheep, suggesting that BS contain proinflammatory metabolites. In this study we investigated the mechanism(s) responsible for this bronchial effect. BS were obtained from 48 h cultures and

Page 1 of 1